Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (152)	4/11/1999 6:45:00 PM
From: scaram(o)uche	Respond to of 52153

from the Tribune...... "Once the object of scientific derision, angiogenesis has become the most talked about topic in cancer research." I've followed Folkman's work since I was at Bayer (Cutter) in the mid-80s..... an ex-boss was a Folkman follower. I can't remember a time when his work met with derision. I do not believe that his molecules have any particular competitive advantage, but the concept has always seemed sound. Good! I was hoping, given AACR, that angiogenesis would stay in front of everyone's eyes this week, but I didn't expect ENMD and Folkman to chip in again. "I want to see every step. I want to see, does it hurt the skin? No. Does it make them shaky? No, they love it." Well, maybe just a tad of derision is reasonable.......